GLP-1 receptor agonists such as semaglutide and tirzepatide have changed obesity care. In the STEP 1 trial, adults taking semaglutide 2.4 mg lost an average of 14.9 percent of body weight over 68 weeks, compared with 2.4 percent on placebo. These medications work largely by reducing appetite and slowing gastric emptying, so people eat less.
That is exactly why nutrition becomes more important, not less. When total intake drops, every bite has to carry more nutrition. A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society makes this its central message: people on GLP-1 therapy need personalized, nutrient-dense, minimally processed diets.
FULL PDF DOWNLOAD: Plantrician-FactSheet-GLP1-Nutrition

